Antiepileptic Drugs

Antiepileptic drugs are the first and, for most patients, the only treatment epilepsy ever requires. Around two-thirds of people with epilepsy become seizure-free on medication alone. The difficulty is that the remaining third do not, and no test currently tells a clinician in advance which group a newly diagnosed patient belongs to. Selecting the right molecule still involves a degree of trial and error that the rest of medicine has largely moved past — and closing that gap is the central preoccupation of this session at the Neurology Conference.

What These Drugs Actually Do

More than thirty agents are licensed worldwide, but they converge on a short list of targets: voltage-gated sodium channels, the SV2A synaptic vesicle protein, GABA-A receptors, AMPA and calcium channels, and a small number of pathway-directed mechanisms such as mTOR inhibition. Understanding which drug belongs to which class is not academic. Combining two agents that share a mechanism generally adds toxicity without adding efficacy, which is why mechanistic diversity — not simply adding another prescription — is the principle behind rational polytherapy.

Newer agents are not automatically more effective than older ones. Their advantage lies in tolerability, predictable pharmacokinetics and fewer interactions, and over a treatment course measured in decades that distinction matters more than a marginal difference in seizure counts. This is where the pharmacology intersects with the wider receptor and signalling science covered under Neuropharmacology.

Why the Field Now Says "Antiseizure Medication"

In a 2024 position paper, the International League Against Epilepsy recommended retiring both "anticonvulsant" and "antiepileptic drug" in favour of antiseizure medication (ASM).

The change is substantive. "Anticonvulsant" is inaccurate because not every seizure is convulsive. "Antiepileptic" overstates what these compounds do: they suppress seizure generation without altering the underlying epileptogenic process, and stopping the medication leaves the epilepsy unchanged. The ILAE also preferred "medication" to "drug", reflecting what patients report about stigma when their treatment shares a label with substances of abuse. Terminology for a genuinely disease-modifying agent has yet to be settled, largely because no such agent exists.

Both terms remain in circulation — literature before 2024 says AED, newer guidance says ASM. They describe the same class, and both appear across this programme.

The One-Third That Does Not Respond

The ILAE defines drug-resistant epilepsy as failure of adequate trials of two appropriately chosen, tolerated medication regimens to achieve sustained seizure freedom. That definition carries an implicit deadline: once two well-selected agents have failed, the likelihood that a third produces seizure freedom drops to a few percent, and continuing to cycle through monotherapies delays evaluation for surgery, neuromodulation or dietary therapy.

Why resistance occurs is genuinely unsettled. Competing explanations point to efflux transporters at the blood-brain barrier limiting drug concentration at the target, to altered binding properties of the channels and receptors themselves, and to structural network reorganisation that no receptor-level intervention can reach. Sessions here examine the evidence for each alongside the clinical management of the patients concerned — work that connects directly to the diagnostic and classification content under Seizure Disorders and Epilepsy.

What This Session Covers

Presentations span mechanism and target biology, syndrome-specific drug selection and the seizure types that certain agents can actively worsen, pharmacogenomic screening now embedded in routine prescribing, safety in pregnancy and across paediatric and geriatric populations, interaction management in patients under shared care, and the pipeline agents closest to clinical use — potassium channel openers, antisense oligonucleotides for monogenic epilepsies, and the first serious attempts at disease modification rather than symptom suppression.

The programme also addresses a fact that precision medicine tends to obscure. The World Health Organization estimates that around 50 million people worldwide have epilepsy, nearly 80% of them in low- and middle-income countries, and that up to 70% could become seizure-free with appropriate use of antiseizure medicines — yet roughly three quarters of people with epilepsy in low-income countries do not receive treatment at all. Access research sits deliberately alongside the pipeline science, because both describe the same disease.